17 trial(s) found.

A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (optINAVO)

NCT07287150

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (InavoPC)

NCT06982521

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor (ReDiscover-2)

NCT06790693

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (INAVO123)

NCT06757634

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (CELC-G-302)

NCT06736704

A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (SNV4818-101)

NCT06208657

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (OPTIMISE)

NCT05894239

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122)

NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (WITHDRAWN)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (COMPLETED)

NANA (WITHDRAWN)

NCT05646862

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy (INAVO121)

2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (COMPLETED)2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (WITHDRAWN)

QLD4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (COMPLETED)

NANA (WITHDRAWN)

NCT05216432

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (RLY-2608-101)

NCT04929223

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (WO42758)

NCT04802759

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (CO42867)

NCT04085653

Managed Access Programs for BYL719, Alpelisib (CBYL719F12001M)

NCT03970447

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM-AGILE)

NCT03424005

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

ACTRN12624001340527

A Phase 1b, Multi-centre, Open-label, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Activity of Combining Paxalisib with Olaparib or Pembrolizumab/Chemotherapy in Patients with Advanced Breast Cancer (PaxPlus-ABC)

ACTRN12623000096651

LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS

Filters

Recruitment Status

Recruitment Country and State

Phase

Trial Type

Cancer Therapy Class

PI3Kalpha	100%
oestrogen axis	53%
ER	47%
mTOR	35%
mTORC1	35%
PD-1/PD-L1	35%
CDK4	29%
CDK6	29%
PI3K	29%
mTORC2	29%
PI3K delta	24%
AKT	18%
PD-1	18%
PD-L1	18%
CDK4 selective	12%
CDK7	12%
VEGF	12%
ERBB2	12%
PARP	12%
AR	6%
CYP17A1	6%
androgen axis	6%
LAG3	6%
EGFR	6%
KRAS	6%
TIGIT	6%
ATM	6%
FGFR	6%
FGFR1	6%
FGFR1/2/3	6%
FGFR2	6%
FGFR3	6%
FGFR4	6%
KIT	6%
PDGFR	6%
RET	6%
VEGFR	6%
CD40	6%
IL-6	6%
LIV1	6%
Trop2	6%
CTLA4	6%
XPO1	6%

Facility

Cancer Type

ARTICANZ - Beta (ver 0.91)

Search results

target/PI3K-alpha-inhibitor

Filters